Health Care & Life Sciences » Biotechnology | Aurinia Pharmaceuticals Inc.

Aurinia Pharmaceuticals Inc. | Ownership

Companies that own Aurinia Pharmaceuticals Inc.

Name
Shares Held
% Shares Out
Change In Shares
% of Assets
As of Date
FIAM LLC
4,804,481
6.12%
4,804,481
0.05%
12/29/2017
Polar Capital LLP
2,653,347
3.38%
53,147
0.03%
07/31/2018
Goldman Sachs & Co. LLC (Private Banking)
1,834,325
2.34%
592,330
0.01%
06/30/2018
OrbiMed Advisors LLC
1,797,426
2.29%
2,502
0.11%
09/30/2017
Franklin Advisers, Inc.
1,733,200
2.21%
68,800
0.01%
06/30/2018
BlackRock Fund Advisors
978,816
1.25%
-63,832
0%
06/30/2018
Ameriprise Financial Services, Inc. (Investment Management)
299,992
0.38%
40,138
0%
06/30/2018
Hudson Bay Capital Management LP
230,000
0.28%
-70,000
0.04%
06/30/2018
Ironwood Investment Management LLC
218,568
0.28%
33,279
0.83%
06/30/2018
Susquehanna Financial Group LLLP
210,521
0.27%
115,493
0.01%
06/30/2018

About Aurinia Pharmaceuticals

View Profile
Address
4464 Markham Street
Victoria British Columbia V8Z 7X8
Canada
Employees -
Website http://www.auriniapharma.com
Updated 07/08/2019
Aurinia Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company, which engages in the development of a therapeutic drug to treat autoimmune diseases particularly lupus nephritis. The company was founded by Robert Foster, Richard Glickman and Michael Martin on June 16, 1993 and is headquartered in Victoria, Canada. .

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.